Clinical application of oxycodone in painless ultrasonic gastroscopy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041454

Enrollment

Unknown

Registered

2020-12-26

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive tract diseases

Interventions

Group 1:Oxycodone

Group 2:Sufentanil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Forty patients were scheduled to undergo painless ultrasonic gastroscopy under intravenous general anesthesia. 2. Inclusion criteria: aged 18-75 years, normal health, ASA grade I-II, no history of organic digestive system diseases, no history of heart, liver, renal insufficiency, cerebrovascular accidents and other medical diseases. The patients were randomly divided into two groups: group O (oxycodone) and group S (sufentanil).

Exclusion criteria

Exclusion criteria: 1. History of allergy and addiction to opioids and other narcotic drugs; 2. Severe cardiopulmonary diseases, abnormal liver and kidney functions; 3. Unable to cooperate and reject participants.

Design outcomes

Primary

Measure	Time frame
Blood pressure;	—

Countries

China

Contacts

Public ContactZhang Zhengzheng

Wuxi People's Hospital affiliated to Nanjing Medical University

aniu1120@163.com+86 13961859520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026